Theodore E. Liston

Theodore E. Liston

Auto-generated profile, based on publicly available information

Theodore E. Liston

Astrocyte Pharmaceuticals Inc., Groton, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
LDLi Di
Li Di
JUJohn P. Umland
John P. Umland
GCGeorge Chang
George Chang
YHYouping Huang
Youping Huang
ZLZhen Lin
Zhen Lin
TLTheodore E. Liston
Theodore E. Liston
Species independence of brain tissue binding was assessed with a large number of structurally diverse compounds using equilibrium dialysis with brain homogenates of seven species and strains (Wistar Han rat, Sprague-Dawley rat, CD-1 mouse, Hartley guinea pig, beagle dog, cynomolgus monkey, and human). The results showed that the fractions unbound of the seven species and strains were strongly correlated with correlation coefficients ranging from 0.93 to 0.99. The cross-species/strain correlations were not significantly different from the interassay correlation with the same species. The linear correlation between Wistar Han and other species had a slope close to 1 and an intercept near 0. Based on orthogonal statistical analysis, no correction is needed for extrapolation of fraction unbound from Wistar Han rat to the other species or strains. Hence, brain tissue binding of Wistar Han rat can be used to obtain binding of other species and strains in drug discovery.

1 January 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
TLTheodore E. Liston
Theodore E. Liston
AHAldric Hama
Aldric Hama
Johannes BoltzeJohannes Boltze
Johannes Boltze
RPRussell B. Poe
Russell B. Poe
TNTakahiro Natsume
Takahiro Natsume
JLJames D. Lechleiter
James D. Lechleiter
Background and Purpose: Treatment with A1R/A3R (adenosine A1 and A3 receptor) agonists in rodent models of acute ischemic stroke results in significantly reduced lesion volume, indicating activation of adenosine A1R or A3R is cerebroprotective. However, dosing and timing required for cerebroprotection has yet to be established, and whether adenosine A1R/A3R activation will lead to cerebroprotection in a gyrencephalic species has yet to be determined. Methods: The current study used clinical study intervention timelines in a nonhuman primate model of transient, 4-hour middle cerebral artery occlusion to investigate a potential cerebroprotective effect of the dual adenosine A1R/A3R agonist AST-004. Bolus and then 22 hours intravenous infusion of AST-004 was initiated 2 hours after transient middle cerebral artery occlusion. Primary outcome measures included lesion volume, lesion growth kinetics, penumbra volume as well as initial pharmacokinetic-pharmacodynamic relationships measured up to 5 days after transient middle cerebral artery occlusion. Secondary outcome measures included physiological parameters and neurological function. Results: Administration of AST-004 resulted in rapid and statistically significant decreases in lesion growth rate and total lesion volume. In addition, penumbra volume decline over time was significantly less under AST-004 treatment compared with vehicle treatment. These changes correlated with unbound AST-004 concentrations in the plasma and cerebrospinal fluid as well as estimated brain A1R and A3R occupancy. No relevant changes in physiological parameters were observed during AST-004 treatment. Conclusions: These findings suggest that administration of AST-004 and combined A1R/A3R agonism in the brain are efficacious pharmacological interventions in acute ischemic stroke and warrant further clinical evaluation.

31 October 2020 in Purinergic Signalling
Verified
Journal Article
Closed access
PDF file
TLTheodore E. Liston
Theodore E. Liston
SHSonja Hinz
Sonja Hinz
CMChrista E. Müller
Christa E. Müller
DHDeborah M. Holstein
Deborah M. Holstein
JWJay Wendling
Jay Wendling
JLJames D. Lechleiter
James D. Lechleiter

1 October 2021 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
EBEda Bozdemir
Eda Bozdemir
FVFabio A. Vigil
Fabio A. Vigil
SCSang H. Chun
Sang H. Chun
LELiliana Espinoza
Liliana Espinoza
VBVladislav Bugay
Vladislav Bugay
JLJames D. Lechleiter
James D. Lechleiter

1 December 2024 in Stroke
Verified
Journal Article
Closed access
LMLisa M. Manna
Lisa M. Manna
JHJuan Hernandez
Juan Hernandez
DHDawn E. Hunt
Dawn E. Hunt
GLGéza Lakner
Géza Lakner
MMMark A. Matson
Mark A. Matson
TLTheodore E. Liston
Theodore E. Liston
BACKGROUND: AST-004 is a small-molecule adenosine A1/A3 receptor agonist that has exhibited significant cerebroprotective efficacy in preclinical models of acute ischemic stroke and traumatic brain injury. The primary objectives of this clinical phase I first-in-human study were to evaluate the safety and tolerability profile of single ascending intravenous doses in healthy subjects. The secondary objectives were to characterize the single-dose pharmacokinetic profiles in plasma, cerebrospinal fluid (CSF), and urine. METHODS: In part 1 of the study, AST-004 was administered in ascending dose cohorts of 5, 25, 50, 75, and 100 mg, with 6 subjects in each cohort receiving the study drug and 2 receiving placebo. In part 2, all 12 subjects received a 100 mg IV infusion of the study drug followed by a single CSF collection per subject via lumbar puncture at 20, 40, or 60 minutes after infusion. RESULTS: A total of 42 subjects received AST-004, with no severe or serious adverse events observed. Twelve of these subjects experienced a treatment-emergent adverse event, the most frequent across groups being headache. In part 2, pharmacokinetic analyses confirmed that AST-004 was distributed in the CSF, with the CSF-to-plasma ratio increasing over the 3 timepoints sampled. The mean half-life was 1.1 to 1.4 hours for doses of 25 to 100 mg, and the geometric mean maximum plasma concentration obtained in the highest dosing cohort (100 mg) was 2232±428 ng/mL. CONCLUSIONS: AST-004 was safe and well-tolerated at plasma concentrations 3 to 8× higher than those associated with significant efficacy in astrocyte’s preclinical primate stroke efficacy studies, with CSF concentrations highest at the 60-minute collection timepoint, the last timepoint tested. This study supports additional clinical investigations, including evaluation of an extended infusion to support the phase 2 program in stroke and traumatic brain injury.

1 July 2024 in Stroke
Verified
Journal Article
Closed access
TLTheodore E. Liston
Theodore E. Liston
DHDeborah Holstein
Deborah Holstein
DSDerek Solt
Derek Solt
DLDamian Lozano
Damian Lozano
WKWilliam S. Korinek
William S. Korinek
JLJames D. Lechleiter
James D. Lechleiter
BACKGROUND: AST-004, a small molecule agonist of the adenosine A1 and A3 receptors, is a potential cerebroprotectant for patients with acute stroke and is currently in clinical trials. Drug-drug interactions are critically important to assess in the context of acute stroke care. Lytic therapy with tPA (tissue-type plasminogen activator)–induced plasmin formation (alteplase) is the only available pharmacotherapy for acute stroke. Consequently, it is imperative to evaluate potential interactions between AST-004 and tPAs such as alteplase and tenecteplase. METHODS: The interactions between AST-004 and tPAs were evaluated in 3 ways in preparation for AST-004 phase II trials. First, the metabolic stability of AST-004 was determined in the presence of alteplase and plasmin. Second, the potential for AST-004 to influence the thrombolytic efficacy of alteplase and tenecteplase was evaluated with an in vitro assay system utilizing a fluorogenic substrate of plasmin. Finally, the potential for AST-004 to influence the thrombolytic efficacy of alteplase was also determined with an in vitro thrombolysis assay of human blood thrombi. RESULTS: Neither alteplase nor plasmin affected the stability of AST-004 in vitro. In 2 different in vitro systems, AST-004 had no effect on the ability of alteplase or tenecteplase to generate plasmin, and AST-004 had no effect on the thrombolytic efficacy of alteplase to lyse blood clots in human blood. CONCLUSIONS: These studies indicate that there will be no interactions between AST-004 and tPAs such as alteplase or tenecteplase in patients with stroke undergoing thrombolytic therapy.